CN105688217A - Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix - Google Patents

Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix Download PDF

Info

Publication number
CN105688217A
CN105688217A CN201610044368.7A CN201610044368A CN105688217A CN 105688217 A CN105688217 A CN 105688217A CN 201610044368 A CN201610044368 A CN 201610044368A CN 105688217 A CN105688217 A CN 105688217A
Authority
CN
China
Prior art keywords
parts
patch
external use
prepared
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610044368.7A
Other languages
Chinese (zh)
Inventor
张高红
易碧芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Bainuokang Biological Medicine Development Co Ltd
Original Assignee
Guizhou Bainuokang Biological Medicine Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Bainuokang Biological Medicine Development Co Ltd filed Critical Guizhou Bainuokang Biological Medicine Development Co Ltd
Priority to CN201610044368.7A priority Critical patent/CN105688217A/en
Publication of CN105688217A publication Critical patent/CN105688217A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0625—Warming the body, e.g. hyperthermia treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a matrix for an external patch and the external patch as well as a mammary gland hyperplasia treating patch prepared from the matrix. The matrix is prepared from all or part of glycerol, ethylenediaminetetraacetic acid, ethylparaben, sodium polyacrylate, crospovidone, far-infrared powder, tartaric acid, sodium carboxymethylcellulose, gelatin, polyvinyl alcohol, a penetrating agent, triethanolamine and purified water. The mammary gland hyperplasia treating patch is prepared from the matrix and a medicinal extract or the matrix. The matrix for the external patch has the functions of relaxing a muscle, driving oxygen and a nutrient in a capillary network to exchange, discharging aged wastes of a fatigue substance, lactic acid and the like, which are accumulated in a body, and removing internal turgescence. The external patch has a certain function of relieving pain. The mammary gland hyperplasia treating patch has the functions of clearing away heat and toxic material, removing turgescence, eliminating stagnation, activating blood circulation to dissipate blood stasis, regulating menstruation, relieving pain, unblocking viscera and inducing the menstruation to relieve menalgia, further, is quick in effect taking, good in curative effect, less in the dosage of the penetrating agent and few in side effects, and can be used for treating various kinds of mammary gland hyperplasia.

Description

External use plaster and cyclomastopathy that a kind of external use plaster substrate and this substrate are made are pasted
Technical field
The present invention relates to a kind of external use plaster substrate and external use plaster that this substrate is made and cyclomastopathy patch, belong to the technical field of medicine or medical apparatus and instruments。
Technical background
Cyclomastopathy is the disease that a kind of gynecological is common。It is apt to occur in the middle-aged women about 25-39 year, because being women's sexual function the most vigorous period during this period of time。Showing as the different parts single-shot of breast or multiple grow some lumps, quality is soft, and obscure boundary is movable, is often accompanied by pain in various degree。Especially, after the moon is premenstrual, tired or during the anxious state of mind such as angry (traditional Chinese medical science claims the stagnation of QI), lump increases, and pain increases the weight of, and after menstruation, lump is obviously reduced, pain relief。Pain is usually distending pain, little tingle。Should reminding, cyclomastopathy changes the possibility into mazalgia, if so suffering from mammary gland have hypertrophy time relatively elder, should remove examination in hospital, in order to diagnose and treat in time。In general, women's sentimentality, one is unsatisfactory, and the fire of conscience is sprung into life, and Liver Channel lactogenesis follows row two side of body, causes that stagnation of QI expectorant coagulates in breast。So, the traditional Chinese medical science is generally adopted the method treatment of soothing liver-QI for relieving depression, promoting the circulation of QI and reducing phlegm。Furthermore it is also possible to " Qi-tonifying drug " of some Colla cornus cervis of fit applications etc, can gas in promoting the circulation of blood, thus it is best to control breast disease effect。
At present, the method treating cyclomastopathy mainly has operative therapy and pharmacotherapy。Expenses of surgical treatment is high, and brings misery to patient, postoperative can produce stasis of blood trace over the course for the treatment of, directly influences the profile of breast and attractive in appearance, and the medicines of great majority treatment cyclomastopathy, unsatisfactory curative effect, side effect is big, is unfavorable for healthy。
Summary of the invention:
The technical problem to be solved is in that, it is provided that external use plaster and cyclomastopathy that a kind of external use plaster substrate and this substrate are made are pasted。Described external use plaster substrate can make Marjoram Extract, accelerates blood circulation, reduces penetrating agent consumption；Make body interior warm simultaneously, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating。Described external use plaster has certain lenitive effect。Described cyclomastopathy patch has a heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, blood circulation promoting and blood stasis dispelling, blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, and onset rapidly, good effect, penetrating agent make that consumption is less, side effect is less。Can be used for the cyclomastopathy treated caused by a variety of causes。
For solving above-mentioned technical problem, the present invention realizes by the following technical solutions: a kind of external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 10-60 part, ethylenediaminetetraacetic acid 0.01-10 part, ethyl hydroxybenzoate 0.01-0.4 part, sodium polyacrylate 1-20 part, polyvinylpolypyrrolidone 1-20 part, far-infrared powder 1-20 part, tartaric acid 0.1-10 part, sodium carboxymethyl cellulose 1-20 part, gelatin 0.1-15 part, polyvinyl alcohol 0.5-15 part, penetrating agent 0.1-10 part, triethanolamine 0.1-5 part and purified water 100-200 part。
In aforesaid external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 30-40 part, ethylenediaminetetraacetic acid 0.1-1 part, ethyl hydroxybenzoate 0.1-0.4 part, sodium polyacrylate 5-15 part, polyvinylpolypyrrolidone 5-15 part, far-infrared powder 5-15 part, tartaric acid 1-4 part, sodium carboxymethyl cellulose 6-12 part, gelatin 1-6 part, polyvinyl alcohol 3-9 part, penetrating agent 1-6 part, triethanolamine 1-1.6 part and purified water 140-160 part。
In aforesaid external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 35 parts, ethylenediaminetetraacetic acid 0.5 part, ethyl hydroxybenzoate 0.2 part, sodium polyacrylate 10 parts, polyvinylpolypyrrolidone 5 parts, far-infrared powder 5 parts, 2 parts of tartaric acid, sodium carboxymethyl cellulose 9 parts, 3 parts of gelatin, polyvinyl alcohol 6 parts, penetrating agent 3 parts, triethanolamine 1.3 parts and purified water 150 parts。
In aforesaid external use plaster substrate, described penetrating agent is azone；Or be prepared from after being mixed by the Borneolum Syntheticum 10-30 part calculated by weight, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part；
Specifically, described penetrating agent calculates by weight, Borneolum Syntheticum 10-30 part, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part are prepared from after mixing。
A kind of external use plaster, counts by weight percentage, aforesaid external use plaster substrate 80%-100%, drug extract or medicated powder surplus is prepared from。
In aforesaid external use plaster, described external use plaster is hydrogel adhesive, and the carrier material used by described hydrogel adhesive is non-weaving cloth, and described non-weaving cloth is for refusing water cloth。
In aforesaid external use plaster, the preparation method of described external use plaster is:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B；
3. take drug extract or medicated powder, tartaric acid, triethanolamine are sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C；Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C；
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute；
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product；
Specifically, the preparation method of described external use plaster is:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 2 hours, obtain solution B；
3. take drug extract, tartaric acid, triethanolamine are sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C；Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C；
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 5 minutes；
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。
A kind of cyclomastopathy patch, for aforesaid external use plaster, wherein, described drug extract calculates according to composition by weight, Herba Taraxaci 10-20 part, Radix Bupleuri 5-14 part, Pericarpium Citri Reticulatae 5-14 part, Rhizoma Cyperi 5-14 part, Pericarpium Citri Reticulatae Viride 5-15 part, Rhizoma Corydalis 6-18 part, Fructus Toosendan 6-18 part, Poria 6-18 part, Radix Paeoniae Alba 6-18 part, Radix Curcumae 6-18 part, Sargassum 6-18 part, Rhizoma Curcumae 6-18 part, Herba Leonuri 10-20 part, Retinervus Luffae Fructus 1-8 part and Spica Prunellae 7-15 part are prepared from。
In aforesaid cyclomastopathy patch, described drug extract is prepared from by Herba Taraxaci 15 parts, Radix Bupleuri 9 parts, Pericarpium Citri Reticulatae 9 parts, Rhizoma Cyperi 9 parts, 10 parts of Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis 12 parts, Fructus Toosendan 12 parts, 12 parts of Poria, the Radix Paeoniae Alba 12 parts, Radix Curcumae 12 parts, Sargassum 12 parts, Rhizoma Curcumae 12 parts, Herba Leonuri 15 parts, Retinervus Luffae Fructus 4 parts and Spica Prunellae 11 parts。
In aforesaid cyclomastopathy patch, the preparation method of described drug extract is: take recipe quantity medical material, adds 6-8 times amount soak by water secondary, each 1-3h, filters, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 24-48 hour, take supernatant, reclaiming ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product；
Specifically, the preparation method of described drug extract is: take recipe quantity medical material, boiling secondary, first time adds 8 times amount soak by water 2h, and second time adds the soak by water 1.5h of 6 times amount, filters, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding so that it is alcohol content reaches 70%, mixing, stand 36 hours, take supernatant, reclaim ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
External use plaster substrate of the present invention is by being partly or entirely prepared from glycerol, ethylenediaminetetraacetic acid, ethyl hydroxybenzoate, sodium polyacrylate, polyvinylpolypyrrolidone, far-infrared powder, tartaric acid, sodium carboxymethyl cellulose, gelatin, polyvinyl alcohol, penetrating agent, triethanolamine and purified water, wherein, glycerol and glycerol, be without the sweet clear and bright thick liquid of color and taste。Odorless。There is warm sweet taste。It is commonly called as glycerol, moisture can be absorbed from air, also can absorb hydrogen sulfide, Blausure (German) and sulfur dioxide。It is insoluble in benzene, chloroform, carbon tetrachloride, Carbon bisulfide, petroleum ether and oils。Glycerol is the framework ingredient of triglyceride molecule。When human body takes in edible fat, triglyceride therein decomposes through internal metabolism, forms glycerol and is stored in adipose cell。Therefore, the end product of Triglyceride Metabolism in Patients is glycerol and fatty acid。Can be used as solvent, lubricant, medicament and sweeting agent。Ethylenediaminetetraacetic acid energy and Mg2+、Ca2+、Mn2+、Fe2+Deng a kind of chelating agen that bivalent metal ion combines。Owing to the effect of most nucleic acid enzymes and some protease needs Mg2+, therefore the conventional inhibitor doing nuclease, protease；Can also be used for the heavy-metal ion removal inhibitory action to enzyme。Ethyl hydroxybenzoate is white crystals thing, mildly bitter flavor, fiber crops of burning。It is mainly used as the sterilization antiseptic of food, cosmetics, medicine, is also used for feed anticorrosion agent。Sodium polyacrylate is a kind of new functional macromolecule material and important chemical products, and solid product is white (or light yellow) bulk or powder, and liquid form product is colourless (or faint yellow) thick liquid。It is dissolved in the media such as cold water, warm water, glycerol, propylene glycol, variations in temperature is stable, there is the effect of fixing metal ions, the metal ion negative influence to product can be stoped, be a kind of surfactant with multiple property。Polyvinylpolypyrrolidone is water-insoluble tablet disintegrant, direct compression and in dry or wet pelletizing press sheet technique working concentration be 2-5%；Polyvinylpolypyrrolidone can show rapidly high capillary activity and excellent hydration capability, almost without the tendency of gel；Research shows: the size of polyvinylpolypyrrolidone granule affects the disintegrate of antipyretic-antalgic sheet strongly, and what polyvinylpolypyrrolidone that granule is big was smaller can play disintegration faster。Polyvinylpolypyrrolidone is very excellent disintegrating agent, uses 1-2% in tablets, just can obtain the disintegration of other conventional common disintegrants, and there is good re-workability, namely reclaim and add man-hour, it is not necessary to add the disintegrating agent of volume, be referred to as super-disintegrant。Tartaric acid (tartaricacid), i.e. 2,3 dihydroxybutanedioic acid, is that a kind of carboxylic acid is present in various plants if Fructus Vitis viniferae and tamarind are also one of organic acid main in wine。Food can be made to have tart flavour as the antioxidant added in food。The maximum purposes of tartaric acid is beverage additive。Also it is pharmaceutical industries raw material。In mirror industry processed, tartaric acid is an important auxiliary agent and reducing agent, it is possible to control the formation speed of silver mirror, it is thus achieved that very homogeneous coating。Sodium carboxymethyl cellulose, (also known as: sanlose, carboxymethyl cellulose, CMC, Carboxymethyl, CelluloseSodium, SodiumsaltofCaboxyMethylCellulose) it is that the world today uses cellulose kind widest in area, that consumption is maximum。Food industry is used as thickening agent, medical industry is used as pharmaceutical carrier, daily chemical industry is used as adhesive, resists dignified dose again。Printing and dyeing industry is used as the protecting colloid etc. of sizing agent and printing gum。Can as oil recovery fracturing fluid composition in petrochemical industry。Gelatin (Gelatin), it does not have fixing structure and relative molecular weight, is degraded by the collagenous portion in the connective tissues such as animal skin, bone, sarolemma, flesh evil spirit and becomes thin slice or the powder of white or faint yellow, translucent, micro-strip gloss；It is a kind of colorless and odorless, non-volatility, transparent hard amorphous material, dissolve in hot water, insoluble in cold water, but can slowly imbibition soften, gelatin can absorb the water being equivalent to weight 5-10 times。Gelatin is one of very important native biopolymer material, has been widely used in food, medicine and chemical industry。Polyvinyl alcohol, organic compound, white plates, cotton-shaped or pulverulent solids, tasteless。It is dissolved in water (more than 95 DEG C), insoluble in gasoline, kerosene, vegetable oil, benzene, toluene, dichloroethanes, carbon tetrachloride, acetone, ethyl acetate, methanol, ethylene glycol etc.。It is slightly soluble in dimethyl sulfoxide。Polyvinyl alcohol is important industrial chemicals, is used for manufacturing Pioloform, polyvinyl acetal, resistance to gasoline pipeline and vinylon synthetic fibers, fabric-treating agent, emulsifying agent, paper coating, binding agent, glue etc.。The full name of penetrating agent (JFC) is fatty alcohol-polyoxyethylene ether, belongs to nonionic surfactant。Penetrating agent as the term suggests be osmosis, be also have fixing hydrophilic and oleophilic group, can align on the surface of solution, and can make the material that surface tension is remarkably decreased。Triethanolamine, i.e. three (2-ethoxy) amine, it is possible to regard the trihydroxy substituent of triethylamine as。Similar to other aminated compoundss, owing to nitrogen-atoms existing lone pair electrons, triethanolamine tool alkalescence, it is possible to generate salt with mineral acid or organic acid reaction。
The external use plaster that above-mentioned substrate combination is made has certain lenitive effect。Owing to external use plaster is percutaneous drug administration preparation, medicine need to penetrate into body, generation effect by keratodermatitis etc., and therefore general onset time is longer, generally adopts addition penetrating agent to promote drug osmotic。But general chemical enhancers has certain side effect, life-time service may cause skin uncomfortable, external use plaster of the present invention adds far-infrared powder in substrate, the far infrared that far-infrared powder produces is also known as " life light wave ", close with the frequency of vibration of human inner cell's molecule, after its infiltration is internal, the atom of human body cell and the resonance of molecule will be caused, through resonant absorption, between molecule, frictional heat forms thermal response, promotes subcutaneous deep temperature to rise, and makes Marjoram Extract, accelerate blood circulation, reduce penetrating agent consumption。In addition, after substrate of the present invention adds far-infrared powder, the deep and thorough power of far infrared is up to muscle arthrosis depths, make body interior warm, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating, relax the effect ached remarkable。
Cyclomastopathy of the present invention patch is prepared from by Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis, Fructus Toosendan, Poria, the Radix Paeoniae Alba, Radix Curcumae, Sargassum, Rhizoma Curcumae, Herba Leonuri, Retinervus Luffae Fructus, Spica Prunellae and adjuvant。Wherein, Herba Taraxaci (Classification system: TaraxacummongolicumHand.-Mazz.) Compositae, Dandelion herbaceos perennial。Nature and flavor: bitter sweet, cold。Gui Jing: entering liver, stomach warp, function cures mainly: heat-clearing and toxic substances removing, diuresis eliminating stagnation。Control acute mastitis, lymphadenitis, scrofula, furuncle carbuncle toxin, acute conjunctivitis, cold, fever, acute tonsillitis, acute bronchitis, gastritis, hepatitis, cholecystitis, urinary tract infection。Radix Bupleuri, Chinese medicine name。For the medical herbs that " Chinese Pharmacopoeia " includes, medicinal part is the dry root of umbelliferae bupleurum or Radix Bupeuri Scorzonerfolii.。Nature and flavor are bitter, be slightly cold, and return liver, gallbladder meridian。There are reconciling superficies and interior, effect of soothing the liver yang invigorating。For cold, fever, alternate attack of chill and fever, malaria, stagnation of QI due to depression of the liver, sternal rib pain, proctoptosis, uterine prolapse, menoxenia。Pericarpium Citri Reticulatae, Chinese medicine name。Dry mature skin for rutaceae orange CitrusreticulataBlanco and variety thereof。Bitter in the mouth, pungent, warm in nature, there is regulating qi-flowing for strengthening spleen, effect of drying dampness to eliminate phlegm。For distension and fullness in the abdomen, lack of appetite and vomiting, cough with copious phlegm。Rhizoma Cyperi, CyperusrotundusL., Chinese medicine name。Dry rhizome for sedge dried tuber。Nature and flavor: hardship pungent, micro-, micro-sweet are flat。Return liver, spleen, tri-jiao channel。There is dispersing the stagnated live-QI to relieve the stagnation of QI, regulating the flow of QI to ease the stomach, effect of menstruction regulating and pain relieving。Can be used for for stagnation of QI due to depression of the liver, distending pain in the chest and hypochondrium, hernia pain, distending pain of the breast, stagnation of QI in spleen and stomach, gastral cavity abdomen painful abdominal mass is vexed, distension pain, menoxenia, amenorrhea dysmenorrhea。Pericarpium Citri Reticulatae Viride, Chinese medicine name。Peel for the dry young fruit of rutaceae orange CitrusreticulataBlanco and variety thereof or immature fruit。Bitter in the mouth, pungent, warm in nature。Return liver, gallbladder, stomach warp。There is soothing the liver dispelling the stagnated QI, effect that removing food stagnancyization is stagnant。For distending pain in the chest and hypochondrium, hernia pain, nodules of the breast, acute mastitis, stagnation of QI due to dyspepsia, abdominal distention。Rhizoma Corydalis (CorydalisyanhusuoW.T.WangexZ.Y.SuetC.Y.Wu), has another name called: Rhizoma Corydalis, corydalis tuber, rhizoma corydalis, Rhizoma Corydalis etc.。It is Papaveraceae, Corydalis herbaceos perennial, nature and flavor: pungent；Bitter；Temperature；Nontoxic。Gui Jing: liver；Stomach；The heart；Lung；Spleen channel。Cure mainly: invigorate blood circulation；Dissipating blood stasis；Regulate the flow of vital energy；Pain relieving。Main trusted subordinate's all pains of waist knee joint；Menoxenia；Lump in the abdomen；Metrorrhagia；Puerperal blood faints；Lochiorrhea；Traumatic injury。Fructus Toosendan, Chinese medicine name。Dry mature fruit for Meliaceae plant Fructus Toosendan MeLiatoosendanSieb.etZucc.。Nature and flavor: bitter, cold。Return liver, small intestinal, bladder warp。There is soothing the liver expelling the heat-evil, promoting the circulation of QI to relieve pain, effect of parasite killing。For pathogenic fire derived from stagnation of liver-QI, the breast side of body, abdominal distention, hernia pain, abdominal pain due to worm stagnation。Poria, Chinese medicine name。Dry sclerotia for On Polyporaceae Poria Poriacocos (Schw.) Wolf。Sweet in the mouth, light, property is put down。GUIXIN, lung, spleen, kidney channel。Promoting diuresis to eliminate damp pathogen, spleen invigorating, mind calming。For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia。The Radix Paeoniae Alba (formal name used at school: PaeonialactifloraPall.), also referred to as Paeonia sterniana Fletcher in Journ., is Ranunculaceae Paeonia plant。Suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating。For dizziness of having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat。Radix Curcumae, Chinese medicine name。Dried root for zingiberaceous plant RADIX CURCUMAE CurcumarcenyujinY, H.ChenetC.Ling, Rhizoma Curcumae Longae CurcumalongaL., Guangxi zedoary CurcumakwangsiensisS.G.LeeetC.F.Liang or Rhizoma Curcumae CurcumaphaeocaulisVal.。Nature and flavor: pungent, bitter, cold。Return liver, the heart, lung meridian。Promoting blood circulation and stopping pain, promoting QI circulation for relieving depression, clear away heart-fire removing heat from blood, effect of promoting the function of the gallbladder to alleviate jaundice。Coercing twinge for breast, obstruction of qi in the chest and cardialgia, amenorrhea dysmenorrhea, distending pain of the breast, calentura coma, epilepsy is gone mad, and heat in blood tells nosebleed, jaundice dark coloured urine。Sargassum, Classification system: SARGASSUM, nature and flavor: bitter in the mouth, salty, cold in nature, nontoxic。Gui Jing: lung；Spleen；Kidney；Liver stomach warp。Effect: softening the hard mass；Expectorant；Diuretic；Detumescent。Thyromegaly, item submental lymph nodes tuberculosis。Eliminating stagnation gas carbuncle, abdomen inner product block, distending pain, abdomen hollow are rung。Also can descend 12 kinds of edema, treat and between skin, gather sudden and violent bursting, stay depressed heat, diuresis。Cure mainly: scrofula；Goiter；Gather；Edema；Beriberi；Painful and swollen testis；(Epileptic is ruined) hernia。Rhizoma Curcumae, Latin name: Curcumazedoaria (Christm.) Rosc., Rhizoma Curcumae is Zingiberaceae, Curcuma perennial root draft, meridian distribution of property and flavor: pungent, bitter, temperature。Return liver, spleen channel。There are removing blood stasis circulation of qi promoting, removing food stagnancy pain relieving。For abdominal pain due to blood stasis, hepatosplenomegaly, trusted subordinate's distending pain, gathering, women's blood stasis amenorrhea, traumatic injury is had a pain effect of eating accumulation。Herba Leonuri, Classification system: Leonurusartemisia (Laur.) S.Y.HuF, for Labiatae, mother wort plant, summer-flowering。Acrid in the mouth is bitter, cool, invigorates blood circulation, silt of dispelling, regulating menstruation, disappear water, treats menoxenia, and vaginal bleeding during pregnancy is had difficult labour, retention of placenta, puerperal blood faints, abdominal pain due to blood stasis, metrorrhagia and metrostaxis, hematuria, rushes down blood, carbuncle skin infection。Retinervus Luffae Fructus, VegetableSpongeofLuffa, for the vascular bundle of cucurbitaceous plant Fructus Luffae or the mature fruit of Guangdong Fructus Luffae。There is dredge the meridian passage, effect of removing toxic substances and promoting subsidence of swelling。Spica Prunellae (formal name used at school: PrunellavulgarisL), the property of medicine: pungent, bitter, cold。Return liver, gallbladder meridian。Effect: clearing away heat-fire, improving eyesight, mass dissipating and swelling eliminating。
Drug extract of the present invention with Herba Taraxaci, Radix Bupleuri for principal agent, wherein Herba Taraxaci heat-clearing and toxic substances removing, dispersing swelling and dissipating binds (especially kind disappear acute mastitis), Radix Bupleuri a surname thoroughly dredges and reaches, compatible with Pericarpium Citri Reticulatae Viride, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Rhizoma Corydalis, Fructus Toosendan, there is depressed liver-energy dispersing and QI regulating pain relieving, adjust the merit of smooth QI and blood；Poria, Radix Paeoniae Alba spleen invigorating, easing the affected liver to relieve pain；Radix Curcumae depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling；Sargassum vanishing sputum and dispelling knot；Rhizoma Curcumae, Herba Leonuri blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, stagnant with mutually 5 promoting the circulation of blood of Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Spica Prunellae purging liver-heat, to change strongly fragrant solution and be tired of, Retinervus Luffae Fructus is apt to, into meridians, removing obstruction in the collateral to relieve pain and Herba Taraxaci compatibility, specially control carbuncle sore tumefacting virus, acute mastitis。If the additionally obvious patient of distending pain of the breast, it is also possible to increasing Olibanum (processed), Myrrha (processed) on the basis of this side, Olibanum (processed) is apt to key to regulate the flow of vital energy, the kind blood stasis dispelling of Myrrha (processed) is with treating blood disorders, and two medicines share to strengthen the effect of the logical internal organs of a surname, inducing menstruation to relieve menalgia。Said medicine prescription, each raw material has good synergism, plays heat-clearing and toxic substances removing altogether, dispersing swelling and dissipating binds (the especially kind acute mastitis that disappears), blood circulation promoting and blood stasis dispelling, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, the cyclomastopathy caused by a variety of causes can be treated, evident in efficacy, have no side effect。
The extractum that said medicine is made and substrate combination of the present invention, in the cyclomastopathy made patch, far-infrared powder can make Marjoram Extract, accelerate blood circulation, the absorption of medicine can be promoted, improve the utilization rate of medicine, so that cyclomastopathy of the present invention patch onset is rapid, better efficacy。
In addition, cyclomastopathy of the present invention patch makes hydrogel adhesive, hydrogel adhesive is the high absorbency material of the macromolecular compound with three-dimensional net structure and water composition, it can swell in water significantly but be not dissolved in water, water is subject to the effects such as bonding, constraint and loses flowability, it is possible to keep certain shape。Hydrogel is widely present in nature, and is and human organ immediate synthetic material in structure and performance。Cyclomastopathy illing skin is more sensitive, patients is it is also possible that the ragazza of non-suckling, other patches such as cataplasma often need to by medical adhesive tape when using, after using medical adhesive tape to stick, not easily tear, and it is when tearing, skin irritation is very big, meanwhile, when other patches such as Babu cream make, usually adopting non-woven fabrics is carrier, and non-woven fabrics can ooze cloth, making use very inconvenient, the present invention adopts and refuses water cloth as carrier, uses also without medical adhesive tape, easy to use, when tearing, skin irritation is only small。
Applicant carried out following experiments, the provable present invention has effective effect；
Experimental example 1: pharmacodynamic study
One, analgesic experiment
1. external use plaster of the present invention, is prepared by embodiment 1；Dolantin。
2. animal
Kunming mouse, mice 30,18-22g, male and female half and half。
3. method and result
Mice 30,18-2g, male and female half and half, be randomly divided into 3 groups, often group 10: of the present invention group, dolantin group (25mg/kg), matched group (giving normal saline)。Except dolantin treated animal intraperitoneal injection, all the other treated animals smear medicine or opposite according to thing in left and right metapedes。After medicine 15 minutes, the right metapedes subcutaneous injection 2.5% formaldehyde 0.03ml of every Mus, and coating 1 time, in observing 15 minutes immediately, mice licks the number of times of right metapedes。Test data adopts t inspection to process, lower same。In Table 1。
Table 1 present invention inhibitory action (X ± SD) to licking foot reaction
Result: external use plaster formalin induced pain of the present invention has obvious analgesic activity, mice licks right metapedes number of times and significantly reduces, and compares with matched group, p < 0.05, it was shown that external preparation of the present invention has analgesic activity。
Two, treatment cyclomastopathy experiment
1, laboratory animal: select SPF level health unpregnancy Wistar rat 60,9 week old, body weight 200 ± 20) g, purchased from Chongqing City's Experimental Animal Center。
2, experimental technique
2.1 Experimental agents:
Invention formulation 1, is prepared according to embodiment 1。Invention formulation 2, is prepared by embodiment 2。Ointment for dispersing breast nodules, Qiqihar He Xiang Pharmaceutical Co produces, and 5g/ sheet makes ointment after grinding into powder, 4C Refrigerator store is standby；Tamoxifen, Shandong health pharmaceutcal corporation, Ltd produces, 10mg/ sheet；Estradiol benzoate, Shanghai General Pharmaceutical Co., ltd. produces, and concentration 2mg/ props up；Progesterone, Zhejiang Province XianJu Pharmacy stock Co., Ltd produces, and concentration 10mg/ props up。Serum Sex Hormones measures medicine box (Beijing North Institute of Biological Technology), 10% formaldehyde, 3% chloral hydrate。Prepared by tamoxifen ointment: tamoxifen 1g, Macrogol 4000 48.6g, Macrogol 4000 36.4g, propylene glycol 14mL。By tamoxifen ultrasonic dissolution in propylene glycol, Macrogol 4000 adds heat fusing and PEG400 mixing, and stirring adds in propylene glycol liquid, and stirring, to cold, to obtain final product。4C Refrigerator store is standby。
2.2 animal packet and administrations
Animal natural feeding starts experiment to adapt to environment in 5 days after the 2nd, 3 pairs of breast portion depilations。60 rats are divided into 6 groups by table of random number, often group 10, respectively blank group (A group), simple disease model group (B group), tamoxifen matched group (C group), ointment for dispersing breast nodules matched group (D group), of the present invention group 1 (E group) and of the present invention group 2 (F) group。
Modeling and administration: A group rat femoribus internus injecting normal saline 0.2mL/ pcs/day, continuous 30 days。All the other groups in femoribus internus intramuscular injection estradiol benzoate 0.5mg/kg/d, continuous 25 days, then intramuscular injection flavone 4mg/kg/d, continuous 5 days, manufacture Treatment of Hyperplasia of Mammary Glands in Animal Model。The 2nd, 3 pairs of breast place liniments of C, D group rat while modeling, wherein C group external application tamoxifen ointment 0.1g/ is only, and only, E group and F group external application invention formulation 1 respectively and invention formulation 2,0.1g/ are only for D group external application ointment for dispersing breast nodules 0.1g/。After the rat drug of topical application of each group, all soft massaging breasts 1min。
2.3 observation index and method
Observe the change of the mammary contour of rat every day。Animal, after 30 days, is pressed 300mg/kg through intraperitoneal injection of anesthesia with 3% chloral hydrate, respectively organizes diameter and the height of the 2nd nipple of rats with left with vernier caliper measurement by modeling and coating；Extract blood 3mL in ventral aorta, hand over Nuclear Medicine Department of Hospital Attached to Shandong Chinese Medical Univ., serum measured by radioimmunoassay sex hormone level；Taking the 2nd pair and the 3rd pair breast of rat, 10% formaldehyde is fixed, Pathology Deparment of Hospital Attached to Shandong Chinese Medical Univ., carries out specimens paraffin embedding slices, carries out histological observation after conventional H E dyeing under light microscopic。
2.4 rat breast tissue diagnostic criterias
According to or without cyclomastopathy disease and disease light and heavy degree, rat breast tissue being divided into 4 classes: without hypertrophy, slight hypertrophy, moderate hypertrophy, severe hypertrophy。Without hypertrophy: lobules of mammary gland is hypertrophy not, body of gland quantity is few, and acinus is not expanded, and is in state resting stage。Slight hypertrophy: indivedual acinuses have slight hypertrophy, without expansion, acinus and have secretions in conduit。Moderate hypertrophy: lobules of mammary gland major part hypertrophy, minority acinus has slight expansion, and adenomatosis level increases, acinus and have secretions in conduit。Severe hypertrophy: lobules of mammary gland major part hypertrophy, most acinuses have obvious expansion, and adenomatosis level increases。More secretions is had in acinus and conduit。Group cyclomastopathy degree each under light microscopic is classified by above-mentioned standard。
2.5 Processing for Data Analysis in Physics
SAS8.0 version statistical software is adopted to be analyzed。The comparison comparing employing variance analysis, each treatment group and matched group between measurement data group adopts t inspection。Ranked data CMH X 2 test。
3, experimental result
The measurement result of 3.1 rat height of nipples and diameter
Testing observation in the 30th day: blank group mammary contour is unchanged, other are respectively organized occurs breast swelling all to some extent, wherein notable with sick module change。The measurement result of each group rat height of nipples and diameter is in Table 2。
The measurement result (n=10, x ± s) of the 2nd height of nipples of rats with left and diameter respectively organized by table 2
Note: compare with simple disease model group,+P < 0.01；
Compare with tamoxifen matched group,#P < 0.01；
Compare with of the present invention group 1,&P<0.05。
As seen from table, invention formulation 1 and invention formulation 2 all can substantially suppress the change of the rat height of nipples caused by estrogen and progestogen modeling；Also can substantially suppress the change of rat papilla diameter caused by estrogen and progestogen modeling simultaneously, and invention formulation 2 is better than invention formulation 1。
3.2 respectively organize rat breast tissue morphological observation
Each group rat breast mammary gland tissue observed result is in Table 3。
Rat breast mammary gland tissue observation analysis respectively organized by table 3
Note: compare with simple disease model group,+P < 0.01；
Compare with tamoxifen matched group,#P < 0.01；
Compare with of the present invention group 1,&P<0.05。
As seen from table, subject hydrogel agent can significantly reduce the degree of cyclomastopathy。
3.3 respectively organize Serum Sex Hormones measurement result
Each group Serum Sex Hormones measurement result is in Table 4, table 5。
The measurement result (n=10, x ± s) of Serum Sex Hormones respectively organized by table 4
Note: compare with simple disease model group,+P < 0.01；
Compare with tamoxifen matched group,#P < 0.01；
Compare with of the present invention group 1,&P<0.05。
The measurement result (n=10, x ± s) of Serum Sex Hormones respectively organized by table 5
Note: compare with simple disease model group,+P < 0.01；
Compare with tamoxifen matched group,#P < 0.01；
Compare with of the present invention group 1,&P<0.05。
As seen from table: subject hydrogel agent can significantly reduce estrogen (E2) level of cyclomastopathy rat model, raise progestogen (P) level, substantially reduce cyclomastopathy rat model lactotropin level。Improve the level of serum testosterone (T) and lutropin (LH), and the level of Folliculogenesis element (FSH) can be reduced。
Experimental example 2: performance study
1 research project:
1.1 invention formulation 1, carry out system by embodiment 1 and make；
1.2 invention formulation 2, make by embodiment 2。
2, experimental technique:
2.1 tacks: test according to [7 method A inclined-plane rolling ball method] prescriptive procedure in GB/T4852-2002 tack test method (rolling ball method), the tack of cyclomastopathy patch should no less than 5 seconds。The concrete method of inspection is as follows:
Taking invention formulation 1 and each 3 of invention formulation 2 respectively, remove lid lining, being placed in inclination angle is 300 hang plate central authorities, and cream is towards upper, and top, inclined-plane 10cm and bottom 15cm covers with mylar thick for 0.025mm。Centre reserves 5cm cream face, is freely rolled down along beveled top end by No. 5 steel balls, clings the cream face time and cannot be less than 5 seconds。
2.2 moistures: cyclomastopathy patch is measured by oven drying method, the moisture in cyclomastopathy patch 100g should be not less than 30g。The concrete method of inspection is as follows:
Take invention formulation 1 and each 3 of invention formulation 2 respectively, be laid in evaporating dish, accurately weighed w1, dry 3 hours at 100-105 DEG C, take out, be placed in exsiccator and let cool 30 minutes, accurately weighed w2, the weight according to less loss, calculate water content (%) in test sample。Computational methods are as follows:
2.3 far infrared wavelength tests take invention formulation 1 and each 10 of invention formulation 2 respectively, remove lid lining, check with far infrared detector。
3, experimental result:
3.1 tacks: invention formulation 1 and invention formulation 2 paste tack and be no less than 5 seconds；
3.2 moistures: the moisture 48g in invention formulation 1100g；With the moisture 52g in invention formulation 2100g。
3.3 far infrared waves: invention formulation 1 and invention formulation 2 far infrared wavelength are 10 μm～14 μm, and emissivity is 82.6% and 83.5%。
Conclusion: the viscosity of cyclomastopathy of the present invention patch is good, it is not necessary to just can be affixed on affected part by medical adhesive tape, decreases sending out of patient skin allergic conditions, and water content is high, is conducive to the absorption of active ingredient, better efficacy。Therefore cyclomastopathy of the present invention patch is functional。
Compared with prior art, have the advantages that
1. external use plaster of the present invention has certain lenitive effect。External use plaster of the present invention adds far-infrared powder in substrate, the far infrared that far-infrared powder produces is also known as " life light wave ", close with the frequency of vibration of human inner cell's molecule, after its infiltration is internal, the atom of human body cell and the resonance of molecule will be caused, through resonant absorption, between molecule, frictional heat forms thermal response, promotes subcutaneous deep temperature to rise, and makes Marjoram Extract, accelerate blood circulation, reduce penetrating agent consumption。In addition, after substrate of the present invention adds far-infrared powder, the deep and thorough power of far infrared is up to muscle arthrosis depths, make body interior warm, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating, relax the effect ached remarkable。
2. cyclomastopathy of the present invention patch has heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, blood circulation promoting and blood stasis dispelling, blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, can treat the cyclomastopathy caused by a variety of causes。
3. additionally, by drug extract and substrate combination of the present invention, in the cyclomastopathy made patch, far-infrared powder can make Marjoram Extract, accelerates blood circulation, it is possible to promotes the absorption of medicine, improve the utilization rate of medicine, so that cyclomastopathy of the present invention patch onset is rapid, better efficacy。And the cyclomastopathy patch made has that tack is good, water content is high, osmotic effect is good, and side effect is less waits beneficial effect。
Detailed description of the invention:
Embodiment 1:
Formula: glycerol 35g, ethylenediaminetetraacetic acid 0.5g, ethyl hydroxybenzoate 0.2g, sodium polyacrylate 10g, polyvinylpolypyrrolidone 5g, far-infrared powder 5g, tartaric acid 2g, sodium carboxymethyl cellulose 9g, gelatin 3g, polyvinyl alcohol 6g, penetrating agent 3g, triethanolamine 1.3g and purified water 150g；
The preparation of penetrating agent: be prepared from after being mixed by Borneolum Syntheticum 120g, Mentholum 58g, Oleum Cinnamomi 15g and natural camphor 10g。
Hydrogel adhesive processing technology:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B；
3. take tartaric acid, triethanolamine is sequentially added in solution A, stirs 5-15 minute, after mix homogeneously, obtains solution C；
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute；
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, obtain hydrogel adhesive。
Embodiment 2:
The preparation of drug extract:
Drug extract prescription: Herba Taraxaci 15g, Radix Bupleuri 9g, Pericarpium Citri Reticulatae 9g, Rhizoma Cyperi 9g, Pericarpium Citri Reticulatae Viride 10g, Rhizoma Corydalis 12g, Fructus Toosendan 12g, Poria 12g, Radix Paeoniae Alba 12g, Radix Curcumae 12g, Sargassum 12g, Rhizoma Curcumae 12g, Herba Leonuri 15g, Retinervus Luffae Fructus 4g and Spica Prunellae 11g；
Preparation technology: taking recipe quantity medical material, boiling secondary, first time adds 8 times amount soak by water 2h, second time adds the soak by water 1.5h of 6 times amount, filters, merging filtrate, filtrate is concentrated into the water extracted immersing paste of relative density 1.10-1.20, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 36 hours, take supernatant, reclaiming ethanol, supernatant concentration, to the extractum of relative density 1.2-1.30, to obtain final product；
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: drug extract 10g, glycerol 35g, ethylenediaminetetraacetic acid 0.5g, ethyl hydroxybenzoate 0.2g, sodium polyacrylate 10g, polyvinylpolypyrrolidone 5g, far-infrared powder 5g, tartaric acid 2g, sodium carboxymethyl cellulose 9g, gelatin 3g, polyvinyl alcohol 6g, penetrating agent 3g, triethanolamine 1.3g and purified water 150g；
Penetrating agent prescription: the preparation of penetrating agent: be prepared from after being mixed by Borneolum Syntheticum 120g, Mentholum 58g, Oleum Cinnamomi 15g and natural camphor 10g。
Hydrogel adhesive preparation technology:
1, take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2, take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 2 hours, obtain solution B；
3, take drug extract, tartaric acid, triethanolamine are sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C；
4, take penetrating agent and solution B adds in solution C, stir and make mastic in 5 minutes；
5, the mastic made is spread evenly across refuses, on water cloth, to dry, cut into slices, to obtain final product。
Embodiment 3:
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: glycerol 40g, ethylenediaminetetraacetic acid 1g, polyvinylpolypyrrolidone 15g, far-infrared powder 15g, tartaric acid 4g, sodium carboxymethyl cellulose 12g, gelatin 6g, polyvinyl alcohol 9g, penetrating agent 6g and purified water 160g, described penetrating agent is azone。
Hydrogel adhesive preparation technology:
1. take gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 1.5 hours, obtain solution B；
3. take tartaric acid to add in solution A, stir 15 minutes, after mix homogeneously, obtain solution C；
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 7 minutes；
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。
Embodiment 4:
The preparation of drug extract:
Drug extract prescription: Herba Taraxaci 10g, Radix Bupleuri 5g, Pericarpium Citri Reticulatae 5g, Rhizoma Cyperi 5g, Pericarpium Citri Reticulatae Viride 5g, Rhizoma Corydalis 6g, Fructus Toosendan 6g, Poria 6g, Radix Paeoniae Alba 6g, Radix Curcumae 6g, Sargassum 6g, Rhizoma Curcumae 6g, Herba Leonuri 10g, Retinervus Luffae Fructus 1g and Spica Prunellae 7g；
Preparation technology: take recipe quantity medical material, adds 6 times amount soak by water secondaries, each 1h, filtering, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, ethanol is added in the water extracted immersing paste, stirring while adding so that it is alcohol content reaches 70%, mixing, stand 24 hours, take supernatant, reclaim ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: drug extract 5g, ethylenediaminetetraacetic acid 1g, polyvinylpolypyrrolidone 15g, far-infrared powder 15g, tartaric acid 4g, sodium carboxymethyl cellulose 12g, gelatin 6g, polyvinyl alcohol 9g, penetrating agent 6g and purified water 160g, described penetrating agent is azone。
Hydrogel adhesive preparation technology:
1. take gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 1.5 hours, obtain solution B；
3. take drug extract and tartaric acid adds in solution A, stir 15 minutes, after mix homogeneously, obtain solution C；
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 7 minutes；
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。

Claims (10)

1. an external use plaster substrate, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 10-60 part, ethylenediaminetetraacetic acid 0.01-10 part, ethyl hydroxybenzoate 0.01-0.4 part, sodium polyacrylate 1-20 part, polyvinylpolypyrrolidone 1-20 part, far-infrared powder 1-20 part, tartaric acid 0.1-10 part, sodium carboxymethyl cellulose 1-20 part, gelatin 0.1-15 part, polyvinyl alcohol 0.5-15 part, penetrating agent 0.1-10 part, triethanolamine 0.1-5 part and purified water 100-200 part。
2. external use plaster substrate as claimed in claim 1, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 30-40 part, ethylenediaminetetraacetic acid 0.1-1 part, ethyl hydroxybenzoate 0.1-0.4 part, sodium polyacrylate 5-15 part, polyvinylpolypyrrolidone 5-15 part, far-infrared powder 5-15 part, tartaric acid 1-4 part, sodium carboxymethyl cellulose 6-12 part, gelatin 1-6 part, polyvinyl alcohol 3-9 part, penetrating agent 1-6 part, triethanolamine 1-1.6 part and purified water 140-160 part。
3. external use plaster substrate as claimed in claim 2, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 35 parts, ethylenediaminetetraacetic acid 0.5 part, ethyl hydroxybenzoate 0.2 part, sodium polyacrylate 10 parts, polyvinylpolypyrrolidone 5 parts, far-infrared powder 5 parts, 2 parts of tartaric acid, sodium carboxymethyl cellulose 9 parts, 3 parts of gelatin, polyvinyl alcohol 6 parts, penetrating agent 3 parts, triethanolamine 1.3 parts and purified water 150 parts。
4. the external use plaster substrate as according to any one of claim 1-3, it is characterised in that: described penetrating agent is azone；Or be prepared from after being mixed by the Borneolum Syntheticum 10-30 part calculated by weight, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part。
5. an external use plaster, it is characterised in that: counting by weight percentage, external use plaster substrate 80%-100% according to any one of claim 1-4, drug extract or medicated powder surplus are prepared from。
6. external use plaster as claimed in claim 5, it is characterised in that: described external use plaster is hydrogel adhesive, and the carrier material used by described hydrogel adhesive is non-weaving cloth, and described non-weaving cloth is for refusing water cloth。
7. external use plaster as claimed in claim 6, it is characterised in that: the preparation method of described external use plaster is:
(1) take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A；
(2) take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B；
(3) take drug extract or medicated powder, tartaric acid, triethanolamine are sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C；Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C；
(4) take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute；
(5) mastic made is spread evenly across refuses, on water cloth, to dry, cut into slices, to obtain final product。
8. a cyclomastopathy patch, it is characterized in that: the external use plaster according to any one of claim 5-7, wherein, described drug extract calculates according to composition by weight, Herba Taraxaci 10-20 part, Radix Bupleuri 5-14 part, Pericarpium Citri Reticulatae 5-14 part, Rhizoma Cyperi 5-14 part, Pericarpium Citri Reticulatae Viride 5-15 part, Rhizoma Corydalis 6-18 part, Fructus Toosendan 6-18 part, Poria 6-18 part, Radix Paeoniae Alba 6-18 part, Radix Curcumae 6-18 part, Sargassum 6-18 part, Rhizoma Curcumae 6-18 part, Herba Leonuri 10-20 part, Retinervus Luffae Fructus 1-8 part and Spica Prunellae 7-15 part are prepared from。
9. cyclomastopathy patch as claimed in claim 8, it is characterised in that: described drug extract is prepared from by Herba Taraxaci 15 parts, Radix Bupleuri 9 parts, Pericarpium Citri Reticulatae 9 parts, Rhizoma Cyperi 9 parts, 10 parts of Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis 12 parts, Fructus Toosendan 12 parts, 12 parts of Poria, the Radix Paeoniae Alba 12 parts, Radix Curcumae 12 parts, Sargassum 12 parts, Rhizoma Curcumae 12 parts, Herba Leonuri 15 parts, Retinervus Luffae Fructus 4 parts and Spica Prunellae 11 parts。
10. cyclomastopathy is pasted as claimed in claim 8 or 9, it is characterized in that: the preparation method of described drug extract is: take recipe quantity medical material, add 6-8 times amount soak by water secondary, each 1-3h, filter, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 24-48 hour, take supernatant, reclaiming ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
CN201610044368.7A 2016-01-22 2016-01-22 Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix Pending CN105688217A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610044368.7A CN105688217A (en) 2016-01-22 2016-01-22 Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610044368.7A CN105688217A (en) 2016-01-22 2016-01-22 Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix

Publications (1)

Publication Number Publication Date
CN105688217A true CN105688217A (en) 2016-06-22

Family

ID=56228515

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610044368.7A Pending CN105688217A (en) 2016-01-22 2016-01-22 Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix

Country Status (1)

Country Link
CN (1) CN105688217A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108310155A (en) * 2018-02-23 2018-07-24 广西中医药大学 A kind of graphene curing mammary gland hyperplasia patch and preparation method thereof
CN109224004A (en) * 2018-12-10 2019-01-18 陕西太白山天然植物开发有限公司 A kind of external use plaster and preparation method thereof for treating the proliferation of mammary gland

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102188580A (en) * 2011-05-10 2011-09-21 浙江省中医药研究院 Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof
CN102397443A (en) * 2010-09-17 2012-04-04 复旦大学 Stagnation eliminating and pain stopping babu paste for treating proliferation of mammary gland and preparation method thereof
CN103705937A (en) * 2014-01-09 2014-04-09 贵州康琦药械有限公司 Medicinal plaster substrate, medicinal plaster using the substrate and preparation method thereof
CN105497261A (en) * 2016-01-22 2016-04-20 贵州康琦药械有限公司 Matrix of patch for external use and patch and sleeping-aid patch made from matrix

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397443A (en) * 2010-09-17 2012-04-04 复旦大学 Stagnation eliminating and pain stopping babu paste for treating proliferation of mammary gland and preparation method thereof
CN102188580A (en) * 2011-05-10 2011-09-21 浙江省中医药研究院 Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof
CN103705937A (en) * 2014-01-09 2014-04-09 贵州康琦药械有限公司 Medicinal plaster substrate, medicinal plaster using the substrate and preparation method thereof
CN105497261A (en) * 2016-01-22 2016-04-20 贵州康琦药械有限公司 Matrix of patch for external use and patch and sleeping-aid patch made from matrix

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
侯雪梅等: "水凝胶贴剂的研究进展及目前存在的问题", 《药学服务与研究》 *
元英进: "《现代制药工艺学 下》", 31 January 2006 *
吴文芝: "乳癖汤治疗乳腺增生病40例", 《实用中医药杂志》 *
孟胜男: "《药剂学》", 30 September 2011 *
屠佑堂: "《中医实用诊疗大全 下册》", 30 March 2013 *
王广生: "《石油化工原料与产品安全手册》", 31 August 2010 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108310155A (en) * 2018-02-23 2018-07-24 广西中医药大学 A kind of graphene curing mammary gland hyperplasia patch and preparation method thereof
CN109224004A (en) * 2018-12-10 2019-01-18 陕西太白山天然植物开发有限公司 A kind of external use plaster and preparation method thereof for treating the proliferation of mammary gland

Similar Documents

Publication Publication Date Title
CN103041173B (en) Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof
CN103751633A (en) Traditional Chinese medicinal composition for treating varicose vein of lower limb and preparation method thereof
CN105662996A (en) Traditional Chinese medicine mask for treating menstruation-associated acne
CN105688217A (en) Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix
CN104547797A (en) Dampness-affected analgesic cataplasm and preparation method thereof
CN103656572A (en) Traditional Chinese medicine composition, traditional Chinese medicinal compound, plaster and preparation method thereof
CN103690849B (en) Be used for the treatment of the Chinese medicine preparation of Superficial Thrombotic Phlebitis
CN104127831A (en) Traditional Chinese medicine for treating pantalgia after childbirth caused by exogenous pathogen and preparation method thereof
CN103735792B (en) A kind of medicine for the treatment of menoxenia and preparation method thereof
CN101390964A (en) Cataplasm of traditional Chinese medicine for treating hyperosteogeny
CN104367946A (en) Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof
CN104208589A (en) Medicine for treating hyperplasia of mammary glands
CN104352995A (en) Medicine for treating gall-stone and preparation method thereof
CN102614341B (en) Chinese medicinal composition for promoting fracture healing
CN115569167B (en) Traditional Chinese medicine composition for treating burns and scalds as well as preparation method and application thereof
CN102091254A (en) Traditional Chinese medicine composition for relieving swelling after cosmetic surgery and preparation method thereof
CN101822685A (en) Application of asiaticoside
CN106138628A (en) A kind of strong medicine ZHICHUANG GAO and preparation method thereof
CN105998290A (en) Traditional Chinese medicine composition for treating early woman amenorrhea and preparing method thereof
CN103933359A (en) Pharmaceutical composition for dispelling keloid and preparation method of pharmaceutical composition
CN105596687A (en) Traditional Chinese medicine for treating perimenopausal syndrome
CN105535674A (en) A medicine for treating chronic cervicitis
CN105288486A (en) Uterine fibroid treating traditional Chinese medicine composition
CN114748557A (en) Hot compress physiotherapy uterus warming patch for gynecology
CN103784722A (en) Method for controlling estrus synchronization of maria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160622